Topical application of local anesthetics to melanoma increases the efficacy of anti-PD-1 therapy

被引:0
|
作者
Tibensky, Miroslav [1 ,2 ]
Blasko, Filip [1 ,2 ]
Vargovic, Peter [2 ]
Jakubikova, Jana [3 ]
Cholujova, Dana [3 ]
Jakubechova, Jana [3 ]
Mravec, Boris [1 ,2 ]
机构
[1] Comenius Univ, Fac Med, Inst Physiol, Bratislava, Slovakia
[2] Slovak Acad Sci, Biomed Res Ctr, Inst Expt Endocrinol, Bratislava, Slovakia
[3] Slovak Acad Sci, Biomed Res Ctr, Canc Res Inst, Bratislava, Slovakia
关键词
B16F0; cells; immune system; lidocaine; melanoma; neurobiology of cancer; tetracaine; CELL SUBSETS; SYSTEM;
D O I
10.4149/neo_2023_230418N216
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Experimental and clinical data have shown that the nervous system can significantly stimulate the initiation and progression of melanoma. In support of this, approaches that reduce the transmission of signals from peripheral nerves to effector tissues reduce the recurrence of melanoma. Therefore, we investigated the effect of topical application of the local anesthetic Pliaglis (7% lidocaine and 7% tetracaine) on the growth of melanoma induced by intradermal application of B16F0 cells in mice without treatment and in mice treated with the anti-PD-1 antibody. We found that application of Pliaglis to melanoma significantly reduced its growth and this effect was even pronounced in mice treated with the anti-PD-1 antibody. To determine the mechanisms and pathways responsible for the observed effect, the in vitro effect of incubating melanoma cells with lidocaine and/or tetracaine and the in vivo gene expression of cancer and immune-related factors, percentage of immune cells, gene expression of selected neurotransmitter receptors and nerve growth factors in melanoma tissue were studied. We found that lidocaine and tetracaine significantly reduced the viability of B16F0 cells in vitro. In mice with melanoma, Pliaglis potentiated the effect of anti-PD-1 antibody on gene expression of COX-2, IL-1 beta, IL-6, CCL11, F4/80, CD206, and NCR1. In addition, Pliaglis increased the gene expression of a9nACHR and 5-HT2a receptors and decreased the gene expression of nerve growth factor receptor (p75NTR) and p53. We also observed Pliaglis-mediated changes in myeloid populations. Topical application of this local anesthetic cream decreased the CD11b(+)Gr1(-) population and increased the CD11b(+)Gr1(high) population. Our data suggest that Pliaglis reduces melanoma growth through a direct effect on melanoma cells as well as through modulation of the immune response. The involvement of nervous system-related signaling in the inhibitory effect of Pliaglis on melanoma is inconclusive from our data.
引用
收藏
页码:375 / +
页数:16
相关论文
共 50 条
  • [1] Anti-PD-1 Therapy in Melanoma
    Moreno, Blanca Hornet
    Parisi, Giulia
    Robert, Lidia
    Ribas, Anton
    [J]. SEMINARS IN ONCOLOGY, 2015, 42 (03) : 466 - 473
  • [2] Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
    Parakh, Sagun
    Park, John J.
    Mendis, Shehara
    Rai, Rajat
    Xu, Wen
    Lo, Serigne
    Drummond, Martin
    Rowe, Catherine
    Wong, Annie
    McArthur, Grant
    Haydon, Andrew
    Andrews, Miles C.
    Cebon, Jonathan
    Guminski, Alex
    Kefford, Richard F.
    Long, Georgina V.
    Menzies, Alexander M.
    Klein, Oliver
    Carlino, Matteo S.
    [J]. BRITISH JOURNAL OF CANCER, 2017, 116 (12) : 1558 - 1563
  • [3] Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
    Park, J. J.
    Parakh, S.
    Mendis, S.
    Rai, R.
    Lo, S.
    Haydon, A.
    Andrews, M. C.
    Cebon, J.
    Guminski, A.
    Kefford, R.
    Long, G. V.
    Menzies, A. M.
    Klein, O.
    Carlino, M. S.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [4] Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
    Sagun Parakh
    John J Park
    Shehara Mendis
    Rajat Rai
    Wen Xu
    Serigne Lo
    Martin Drummond
    Catherine Rowe
    Annie Wong
    Grant McArthur
    Andrew Haydon
    Miles C Andrews
    Jonathan Cebon
    Alex Guminski
    Richard F Kefford
    Georgina V Long
    Alexander M Menzies
    Oliver Klein
    Matteo S Carlino
    [J]. British Journal of Cancer, 2017, 116 : 1558 - 1563
  • [5] Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma
    Zhao, Lingdi
    Yang, Yonghao
    Ma, Baozhen
    Li, Wei
    Li, Tiepeng
    Han, Lu
    Zhang, Yong
    Shang, Yi-Man
    Lin, Hongwei
    Gao, Quanli
    [J]. JOURNAL OF ONCOLOGY, 2019, 2019
  • [6] The Efficacy of Anti-PD-1 Agents in Acral and Mucosal Melanoma
    Shoushtari, Alexander N.
    Munhoz, Rodrigo R.
    Kuk, Deborah
    Ott, Patrick A.
    Johnson, Douglas B.
    Tsai, Katy K.
    Rapisuwon, Suthee
    Eroglu, Zeynep
    Sullivan, Ryan J.
    Luke, Jason J.
    Gangadhar, Tara C.
    Salama, April K. S.
    Clark, Varina
    Burias, Clare
    Puzanov, Igor
    Atkins, Michael B.
    Algazi, Alain P.
    Ribas, Antoni
    Wolchok, Jedd D.
    Postow, Michael A.
    [J]. CANCER, 2016, 122 (21) : 3354 - 3362
  • [7] Resistance patterns to anti-PD-1 therapy in metastatic melanoma
    Ozgun, Alpaslan
    Sondak, Vernon K.
    Markowitz, Joseph
    [J]. CHINESE CLINICAL ONCOLOGY, 2016, 5 (06)
  • [8] Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
    Bhave, Prachi
    Ahmed, Tasnia
    Lo, Serigne N.
    Shoushtari, Alexander
    Zaremba, Anne
    Versluis, Judith M.
    Mangana, Joanna
    Weichenthal, Michael
    Si, Lu
    Lesimple, Thierry
    Robert, Caroline
    Trojanello, Claudia
    Wicky, Alexandre
    Heywood, Richard
    Tran, Lena
    Batty, Kathleen
    Dimitriou, Florentia
    Stansfeld, Anna
    Allayous, Clara
    Schwarze, Julia K.
    Mooradian, Meghan J.
    Klein, Oliver
    Mehmi, Inderjit
    Roberts-Thomson, Rachel
    Maurichi, Andrea
    Yeoh, Hui-Ling
    Khattak, Adnan
    Zimmer, Lisa
    Blank, Christian U.
    Ramelyte, Egle
    Kaehler, Katharina C.
    Roy, Severine
    Ascierto, Paolo A.
    Michielin, Olivier
    Lorigan, Paul C.
    Johnson, Douglas B.
    Plummer, Ruth
    Lebbe, Celeste
    Neyns, Bart
    Sullivan, Ryan
    Hamid, Omid
    Santinami, Mario
    McArthur, Grant A.
    Haydon, Andrew M.
    Long, Georgina, V
    Menzies, Alexander M.
    Carlino, Matteo S.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (07)
  • [9] Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti-PD-1 Therapy Efficacy
    Montfort, Anne
    Bertrand, Florie
    Rochotte, Julia
    Gilhodes, Julia
    Filleron, Thomas
    Milhes, Jean
    Dufau, Carine
    Imbert, Caroline
    Riond, Joelle
    Tosolini, Marie
    Clarke, Christopher J.
    Dufour, Florent
    Constantinescu, Andrei A.
    De Franca Junior, Nilton
    Garcia, Virginie
    Record, Michel
    Cordelier, Pierre
    Brousset, Pierre
    Rochaix, Philippe
    Silvente-Poirot, Sandrine
    Therville, Nicole
    Andrieu-Abadie, Nathalie
    Levade, Thierry
    Hannun, Yusuf A.
    Benoist, Herve
    Meyer, Nicolas
    Micheau, Olivier
    Colacios, Celine
    Segui, Bruno
    [J]. CANCER IMMUNOLOGY RESEARCH, 2021, 9 (05) : 568 - 582
  • [10] Phase I Study of Androgen Deprivation Therapy in Combination with Anti-PD-1 in Melanoma Patients Pretreated with Anti-PD-1
    Robert, Caroline
    Lebbe, Celeste
    Lesimple, Thierry
    Lundstrom, Eija
    Nicolas, Valerie
    Gavillet, Bruno
    Crompton, Philippa
    Baroudjian, Barouyr
    Routier, Emilie
    Lejeune, Ferdy J.
    [J]. CLINICAL CANCER RESEARCH, 2023, 29 (05) : 858 - 865